![Montserrat Vendrell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Montserrat Vendrell
Direktor/Vorstandsmitglied bei
ORYZON GENOMICS S.A.
Profil
Montserrat Vendrell is an Independent Director at Oryzon Genomics SA since 2025.
Director at Ona Therapeutics SL and Inbrain Neuroelectronics SL.
Board Member at Peptomyc SL since 2017.
Partner at Asabys Partners SGEIC SA since 2025.
Formerly Chairman at Accure Therapeutics SL.
Managing Partner at Altamar Private Equity SGIIC SA from 2016 to 2025.
Education includes a doctorate from the University of Barcelona in 1987, a graduate degree from Universitat Pompeu Fabra in 1997, and a graduate degree from the University of Navarra in 2007.
Aktive Positionen von Montserrat Vendrell
| Unternehmen | Position | Beginn |
|---|---|---|
| ORYZON GENOMICS S.A. | Direktor/Vorstandsmitglied | 28.02.2025 |
Peptomyc SL
 Peptomyc SL Pharmaceuticals: MajorHealth Technology Develops cell penetrating peptides targeting the Myc oncoprotein for cancer treatment | Direktor/Vorstandsmitglied | 01.07.2017 |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets drugs for treatment and cancers and other diseases | Direktor/Vorstandsmitglied | - |
Inbrain Neuroelectronics SL
 Inbrain Neuroelectronics SL Medical SpecialtiesHealth Technology Operates as a medical device company that develops graphene neural interfaces and neuromodulation systems | Direktor/Vorstandsmitglied | - |
Asabys Partners SGEIC SA
 Asabys Partners SGEIC SA Investment ManagersFinance Asabys Partners invests in companies located in Spain, Europe, Israel, Switzerland and the United Kingdom. The firm targets companies operating in the fields of biotechnology, disruptive services, medical devices, health technologies, medTech and digital health. It provides financing for early stage capital requirements with investment size ranging from EUR 3 million. | Private Equity Investor | 01.10.2025 |
Ehemalige bekannte Positionen von Montserrat Vendrell
| Unternehmen | Position | Ende |
|---|---|---|
Altamar Private Equity SGIIC SA /Private Equity/
 Altamar Private Equity SGIIC SA /Private Equity/ Investment ManagersFinance Altamar Private Equity invests in companies located across the globe. The firm targets businesses operating in the life sciences sector including biotechnology, infrastructure, medical devices, diagnostics, genomics, and digital health. It provides equity and debt financing for buyouts, secondary, special situations, and early to growth stage capital requirements. It also makes co-investments. | Private Equity Investor | 01.10.2025 |
Accure Therapeutics SL
 Accure Therapeutics SL Pharmaceuticals: MajorHealth Technology Develops medicines to treat patient suffering from central nervous system | Vorsitzender | - |
Ausbildung von Montserrat Vendrell
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
71
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Oryzon Genomics SA
 Oryzon Genomics SA BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops epigenetics-based therapeutics | Health Technology |
University of Barcelona
 University of Barcelona Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Navarra
 University of Navarra Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universitat Pompeu Fabra
 Universitat Pompeu Fabra Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altamar Private Equity SGIIC SA /Private Equity/
Altamar Private Equity SGIIC SA /Private Equity/ Investment ManagersFinance Altamar Private Equity invests in companies located across the globe. The firm targets businesses operating in the life sciences sector including biotechnology, infrastructure, medical devices, diagnostics, genomics, and digital health. It provides equity and debt financing for buyouts, secondary, special situations, and early to growth stage capital requirements. It also makes co-investments. | Finance |
Peptomyc SL
Peptomyc SL Pharmaceuticals: MajorHealth Technology Develops cell penetrating peptides targeting the Myc oncoprotein for cancer treatment | Health Technology |
Asabys Partners SGEIC SA
Asabys Partners SGEIC SA Investment ManagersFinance Asabys Partners invests in companies located in Spain, Europe, Israel, Switzerland and the United Kingdom. The firm targets companies operating in the fields of biotechnology, disruptive services, medical devices, health technologies, medTech and digital health. It provides financing for early stage capital requirements with investment size ranging from EUR 3 million. | Finance |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets drugs for treatment and cancers and other diseases | Health Technology |
Accure Therapeutics SL
Accure Therapeutics SL Pharmaceuticals: MajorHealth Technology Develops medicines to treat patient suffering from central nervous system | Health Technology |
Inbrain Neuroelectronics SL
Inbrain Neuroelectronics SL Medical SpecialtiesHealth Technology Operates as a medical device company that develops graphene neural interfaces and neuromodulation systems | Health Technology |
